Cadrenal Appoints John P. Sharp Interim CFO; Board Member Steven Zelenkofske Steps Down
CVKD sits 18% above its 52-week low of $2.55.
Summary
Cadrenal Therapeutics appointed John P. Sharp as Interim CFO, effective June 25, 2026, bringing over 30 years of finance experience to the role. This change in financial leadership comes as the company operates under a reiterated going concern warning and a cash runway only into October 2026, as reported in its May 7th 10-Q. Separately, director Steven Zelenkofske resigned from the board, effective June 30, 2026, with the company stating no disagreement was involved. The appointment of an experienced interim CFO is a stabilizing factor for a company facing significant financial challenges.
At the time of this announcement, CVKD was trading at $3.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $2.55 to $14.64. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.